Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held on 21 August 2024.Powered by Capital Market - Live News

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam. DCGI has also granted permission to manufacture and market Finished Dosage Form (FDF) of Cefepime and Enmetazobactam as a dry powder injectable. This formulation is indicated for the treatment of complicated Urinary Tract Infections (cUTI) including acute Pyelonephritis, HospitalAcquired Pneumonia (HAP) including Ventilator-associated pneumonia (VAP), and Bacteremia when it is associated or suspected to be associated with either complicated urinary tract infections or hospital-acquired pneumonia. With this approval, Orchid Pharma intends to improve the treatment landscape for serious infections in India, providing patients with access to advanced and effective therapy options. Anti-Microbial resistance (AMR) is declared as the silent pandemic by UN and WHO and it has contributed to almost 5mn deaths in 2019. In addition to death and disability, AMR has significant economic costs. The World Bank estimates that AMR could result in US$ 1 trillion additional healthcare costs by 2050, and US$ 1 trillion to US$ 3.4 trillion gross domestic product (GDP) losses per year by 2030. This new Combination Drug, provides a powerful treatment option against a range of severe infections caused by resistant bacteria, addressing a critical need in combating antimicrobial resistance.Powered by Capital Market - Live News

Net profit of Orchid Pharma declined 44.27% to Rs 32.96 crore in the quarter ended March 2024 as against Rs 59.14 crore during the previous quarter ended March 2023. Sales rose 3.43% to Rs 217.10 crore in the quarter ended March 2024 as against Rs 209.90 crore during the previous quarter ended March 2023.For the full year,net profit rose 98.99% to Rs 92.17 crore in the year ended March 2024 as against Rs 46.32 crore during the previous year ended March 2023. Sales rose 23.05% to Rs 819.37 crore in the year ended March 2024 as against Rs 665.90 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales217.10209.90 3 819.37665.90 23 OPM %13.3218.90 -13.5112.56 - PBDT38.8033.93 14 125.1870.82 77 PBT30.3826.72 14 91.9516.03 474 NP32.9659.14 -44 92.1746.32 99 Powered by Capital Market - Live News

Orchid Pharma has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, �Enmetazobactam`. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor. This USFDA approval paves the way for the introduction of Enmetazobactam in the United States, the largest pharmaceutical market in the world. The product is expected to be launched within the next couple of quarters in the US market. This New Drug Approval (NDA) allows the use of Exblifep (Cefepime and Enmetazobactam) as an injection for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA. It is a significant development in addressing the global need for affordable and efficacious drugs to combat Anti-Microbial Resistance (AMR). Powered by Capital Market - Live News

Net profit of Orchid Pharma rose 287.75% to Rs 29.43 crore in the quarter ended December 2023 as against Rs 7.59 crore during the previous quarter ended December 2022. Sales rose 38.08% to Rs 220.59 crore in the quarter ended December 2023 as against Rs 159.76 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales220.59159.76 38 OPM %16.048.55 - PBDT39.4614.91 165 PBT30.196.73 349 NP29.437.59 288 Powered by Capital Market - Live News